NextCell Pharma introduces stem cell service for adults

Stem cell company NextCell Pharma AB (“NXTCL”) announces that it is preparing to launch a service for saving adipose (fat) tissue derived stem cells during the first half of 2019. The service allows adults to save their own stem cells for future use. The stem cells are collected by liposuction, purified, processed and frozen in liquid nitrogen. The effort is made in the light of the rapid development of techniques for differentiation of induced pluripotent stem cells, iPS cells, as well as regeneration of tissues for treatment in a variety of indications.

NXTCL is first in Sweden to offer family savings of stem cells from umbilical cord tissue. These stem cells are early, viable and have been only marginally exposed to mutations and environmental impact. The birth is a unique opportunity to save stem cells without any intervention. For all the people who are already born and yet want to secure their own (autologous) stem cells for the future, fat tissue is an attractive alternative. The purpose is to save stem cells when the person is healthy, available later in life for treatment with autologous cells.

“NXTCL is in the middle of a clinical study in which unrelated (allogeneic) umbilical cord stem cells are given to type 1 diabetes patients to limit the autoimmune process. ProTrans treatment is expected to be active in other autoimmune and inflammatory conditions. Differentiation for clinical use of stem cells from both umbilical cord and fatty tissue to the beta cells of the cartilage, bone, muscle, nerve and pancreas is believed to be possible and NXTCL is well positioned to take advantage of these opportunities”, says Mathias Svahn, CEO.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 30th of July 2018.

Stay up to date with the latest development in NextCell Pharma



For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Leo Groenewegen, CFO

Phone: 08-735 5595


About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.


Documents & Links